Loading clinical trials...
Loading clinical trials...
A Phase 2, Prospective, Open-Label Study to Determine the Safety and Efficacy of SB939, A Histone Deacetylase Inhibitor, in Subjects With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (PMF; Post-Polycythemia Vera (PV) Myelofibrosis (MF), Or Post- Essential Thrombosis (ET) MF
Conditions
Interventions
SB939
Locations
1
United States
UT MD Anderson Cancer Center
Houston, Texas, United States
Start Date
November 1, 2010
Primary Completion Date
November 1, 2012
Completion Date
November 1, 2012
Last Updated
January 30, 2014
NCT07445984
NCT01366612
NCT02158858
NCT05969821
NCT02766153
NCT04631211
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions